

Tuberculosis profile: Singapore

Population 2022: 6 million

Estimates of TB burden*, 2022

	Number	(Rate per 100 000 population)
Total TB incidence	3 100 (2 600-3 600)	51 (44-59)
HIV-positive TB incidence	30 (18-44)	0.5 (0.31-0.74)
MDR/RR-TB incidence**	61 (45-77)	1 (0.75-1.3)
HIV-negative TB mortality	26 (22-30)	0.43 (0.36-0.5)
HIV-positive TB mortality	9 (5-13)	0.15 (0.09-0.22)

Estimated proportion of TB cases with MDR/RR-TB*, 2022

New cases	1.9% (1.5-2.4)
Previously treated cases	2.7% (1.3-4.7)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2022	87% (75-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2022	1% (1-1)

TB case notifications, 2022

Total new and relapse	2 674
- % tested with rapid diagnostics at time of diagnosis	92%
- % with known HIV status	81%
- % pulmonary	89%
- % bacteriologically confirmed ^	47%
- % children aged 0-14 years	1%
- % women (aged ≥15 years)	35%
- % men (aged ≥15 years)	64%
Total cases notified	2 681

TB/HIV care in new and relapse TB patients, 2022

	Number	(%)
Patients with known HIV status who are HIV-positive	21	0.97%
- on antiretroviral therapy		

Drug-resistant TB care**, 2022

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	91%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	58%
Laboratory-confirmed cases - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	17
Patients started on treatment - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^^	16
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	6
Patients started on treatment - pre-XDR-TB or XDR-TB ^^^	6
MDR/RR-TB cases tested for resistance to any fluoroquinolone	23

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2021	78%	2 370
Previously treated cases, excluding relapse, registered in 2021	50%	2
HIV-positive TB cases registered in 2021	84%	19
MDR/RR-TB cases started on second-line treatment in 2020	38%	16
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2020	0%	2

TB preventive treatment, 2022

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of household contacts of bacteriologically-confirmed TB cases on preventive treatment	15% (15-15)

* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone


^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2022 and patients who were not laboratory-confirmed


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



HIV-negative TB mortality

(Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2022

(Number)



Cases attributable to five risk factors, 2022

(Number)

